Activity of the investigational fluoroquinolone finafloxacin and seven other antimicrobial agents against 114 obligately anaerobic bacteria

International Journal of Antimicrobial Agents

Volumn 44, Issue 5, 2014, Pages 420-423

  Genzel, G H ^a   Stubbings, W ^b   Stingu C S ^a   Labischinski, H ^b   Schaumann, R ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b MerLion Pharmaceuticals GmbH   (Germany)

Author keywords

Anaerobic bacteria; Finafloxacin; Investigational fluoroquinolone

Indexed keywords

CIPROFLOXACIN; FINAFLOXACIN; IMIPENEM; LEVOFLOXACIN; METRONIDAZOLE; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ACIDITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTEROIDES FRAGILIS; BROTH DILUTION; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; GRAM NEGATIVE ANAEROBIC BACTERIA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PH; ANAEROBIC BACTERIUM; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST;

ANTI-INFECTIVE AGENTS; BACTERIA, ANAEROBIC; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS;

EID: 84908507093     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2014.07.006     Document Type: Article

References (30)

1. W.J. Stubbings, P. Leow, G.C. Yong, F. Goh, B. Körber-Irrgang, and M. Kresken In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions Antimicrob Agents Chemother 55 2011 4394 4397
2. S. Schubert, W.J. Stubbings, and A. Dalhoff Comparative in vitro activities of the novel antibacterial finafloxacin against selected Gram-positive and Gram-negative bacteria tested in Mueller-Hinton broth and synthetic urine Antimicrob Agents Chemother 55 2011 1814 1818
3. P. Leow, W.J. Stubbings, and H. Labischinski Selection and characterisation of finafloxacin, ciprofloxacin and levofloxacin resistant mutants of Escherichia coli 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Diseases Society of America (IDSA) 46th annual meeting 25-28 October 2008, Washington, DC 2008 ASM Press Washington, DC [F1-2043]
4. P.G. Higgins, W.J. Stubbings, H. Wisplinghoff, and H. Seifert Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates Antimicrob Agents Chemother 54 2010 1613 1615
5. C.Y. Goh, H. Labischinski, and W.J. Stubbings Finafloxacin exhibits enhanced activity under acidic and anaerobic conditions 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 12-15 September 2010 2010 ASM Press Boston, MA., Washington, DC [poster E-178]
6. F.M.E. Wagenlehner, C. Wagenlehner, B. Blenk, H. Blenk, S. Schubert, and A. Dalhoff Urinary pharmacokinetics and bactericidal activity of finafloxacin (200 and 800 mg) in healthy volunteers receiving a single oral dose Antimicrob Agents Chemother 57 2011 97 107
7. C.Y. Goh, F. Goh, and W.J. Stubbings In vitro investigation of finafloxacin under conditions simulating lower respiratory tract infection 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 12-15 September 2010 2010 ASM Press Boston, MA. Washington, DC [E177]
8. C.Y. Goh, F. Goh, W.J. Stubbings, H.P. Kroll, and H. Labischinski Bactericidal activity of finafloxacin against difficult to kill growth forms of Escherichia coli 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Diseases Society of America (IDSA) 46th annual meeting 25-28 October 2008, Washington, DC 2008 ASM Press Washington, DC [F1-2042]
9. H. Patel, A. Andresen, A. Vente, H.D. Heilmann, W.J. Stubbings, and M. Seiberling Human pharmacokinetics and safety profile of finafloxacin, a new fluoroquinolone antibiotic, in healthy volunteers Chemotherapy 57 2011 97 107
10. J.S. Solomkin, J.E. Mazuski, J.S. Bradley, K.A. Rodvold, E.J.C. Goldstein, and E.J. Baron Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America Clin Infect Dis 50 2010 133 164
11. E.J.C. Goldstein, D.M. Citron, Y.A. Warren, K.L. Tyrrell, C.V. Merriam, and H. Fernandez In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections Antimicrob Agents Chemother 50 2006 148 155
12. E.J.C. Goldstein, J.S. Solomkin, D.M. Citron, and J.D. Alder Clinical efficacy and correlation of clinical outcomes with in vitro susceptibility for anaerobic bacteria in patients with complicated intra-abdominal infections treated with moxifloxacin Clin Infect Dis 53 2011 1074 1080
13. J.K. Harris, M.A. De Groote, S.D. Sagel, E.T. Zemanick, R. Kapsner, and C. Penvari Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis Proc Natl Acad Sci USA 51 2007 20529 20533
14. DIN, Deutsches Institut für Normung e.V. 2004 Medizinische Mikrobiologie und Immunologie: Diagnostische Verfahren 2004 Beuth Verlag Berlin, Wien, Zürich
15. R. Schaumann, and A.C. Rodloff Activities of quinolones against obligately anaerobic bacteria Antiinfect Agents Med Chem 6 2007 49 56
16. K.G. Naber, and D. Adam Classification of fluoroquinolones Int J Antimicrob Agents 10 1998 255 257
17. J. Sóki, Z. Eitel, G. Terhes, E. Nagy, and E. Urbán ESCMID Study Group on Anaerobic Infections. Occurrence and analysis of rare cfiA-bft doubly positive Bacteroides fragilis strains Anaerobe 23 2013 70 73
18. I. Wybo, D. Van den Bossche, O. Soetens, E. Vekens, K. Vandoorslaer, and G. Claeys Fourth Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria J Antimicrob Chemother 69 2014 155 161
19. E. Nagy, E. Urbán, and C.E. Nord ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe: 20 years of experience Clin Microbiol Infect 17 2011 371 379
20. R. Schaumann, G. Ackermann, B. Pless, M.C. Claros, E.J. Goldstein, and A.C. Rodloff In vitro activities of fourteen antimicrobial agents against obligately anaerobic bacteria Int J Antimicrob Agents 16 2000 225 232
21. R. Schaumann, E. Janssen, M. Funke, C.S. Stîngu, G.H. Genzel, and M. Janssen In vitro activities of levofloxacin, gatifloxacin, moxifloxacin and garenoxacin against Bacteroides fragilis strains evaluated by kill kinetics J Med Microbiol 62 2013 576 581
22. G.E. Stein, and E.J.C. Goldstein Fluoroquinolones and anaerobes Clin Infect Dis 42 2006 1598 1607
23. R. Schaumann, M. Funke, E. Janssen, and A.C. Rodloff In vitro activities of clindamycin, imipenem, metronidazole, and piperacillin-tazobactam against susceptible and resistant isolates of Bacteroides fragilis evaluated by kill kinetics Antimicrob Agents Chemother 56 2012 3413 3416
24. H. Seifert, and A. Dalhoff PRISMA Study Group. German multicentre survey of the antibiotic susceptibility of Bacteroides fragilis group and Prevotella species isolated from intra-abdominal infections: results from the PRISMA study J Antimicrob Chemother 65 2010 2405 2410
25. J.A. Karlowsky, A.J. Walkty, H.J. Adam, M.R. Baxter, D.J. Hoban, and G.G. Zhanel Prevalence of antimicrobial resistance among clinical isolates of Bacteroides fragilis group in Canada in 2010-2011: CANWARD surveillance study Antimicrob Agents Chemother 56 2012 1247 1252
26. A.H. Bruns, J.J. Oosterheert, E.J. Kuijper, J.W. Lammers, S. Thijsen, and A. Troelstra Impact of different empirical antibiotic treatment regimens for community-acquired pneumonia on the emergence of Clostridium difficile J Antimicrob Chemother 65 2010 2464 2471
27. P. Biller, B. Shank, L. Lind, M. Brennan, L. Tkatch, and G. Killgore Moxifloxacin therapy as a risk factor for Clostridium difficile-associated disease during an outbreak: attempts to control a new epidemic strain Infect Control Hosp Epidemiol 28 2007 198 201
28. M.E. Falagas, L. McDermott, and D.R. Snydman Effect of pH on in vitro antimicrobial susceptibility of the Bacteroides fragilis group Antimicrob Agents Chemother 41 1997 2047 2049
29. E.J. Goldstein, V.L. Sutter, Y.Y. Kwok, R.P. Lewis, and S.M. Finegold Effect of carbon dioxide on in vitro susceptibility of anaerobic bacteria to erythromycin Antimicrob Agents Chemother 20 1981 705 708
30. I. Brook, H.M. Wexler, and E.J.C. Goldstein Antianaerobic antimicrobials: spectrum and susceptibility testing Clin Microbiol Rev 5 2013 26 46